Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players In this report you can find an overview […]
2021 Year End Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021
Bought Not Sold Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals Authors: Geoff Meyerson, CEO & Co-Founder
LOCUST WALK NEWS Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust
Locust Walk 2020 Year End Report Each quarter our team at Locust Walk compiles key statistics and trends on strategic
Doubling Down Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk
CATEGORIES News Events Publications ARCHIVE Panel Recording: The Unexpected IPO Boom in Biopharma in Q2 Locust Walk partnered with Applied
CATEGORIES News Events Publications ARCHIVE Geoff Meyerson to Moderate Panel at Crush Life Sciences Board Meeting The Crush Life Sciences
CATEGORIES News Events Publications ARCHIVE Hayato Watanabe, Locust Walk’s SVP, Head of Asia, to Speak on a Panel at BIO
CATEGORIES News Events Publications ARCHIVE Fireside Chat with Geoff Meyerson, Locust Walk’s CEO & Co-Founder, at BIO CEO & Investor